Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
HCWB Stock Summary
Top 10 Correlated ETFs
HCWB
In the News
HCW Biologics Inc (HCWB), Quotient Technology (QUOT) – Smith Micro Software And 3 Other Stocks Under $3 Insiders Are Aggressively Buying
US crude oil futures traded lower this morning on Wednesday. Investors, meanwhile, focused on some notable insider trades.
HCW Biologics to Present at 2022 Virtual Growth Conference Sponsored by the Maxim Group and M-Vest
Founder and CEO, Hing C. Wong, Ph.D., to be guest at “Fireside Chat” Founder and CEO, Hing C. Wong, Ph.D., to be guest at “Fireside Chat”
Masonic Cancer Center To Evaluate HCW Biologics' Bifunctional Fusion Protein In Advanced Cancers
The FDA cleared the Masonic Cancer Center, University of Minnesota to evaluate HCW Biologics Inc's (NASDAQ: HCWB) lead drug candidate, HCW9218, in Phase 1 trial in patients with advanced solid tumors with progressive disease after prior chemotherapies. HCW9218 is an injectable, bifunctional fusion protein complex designed to drive anti-tumor activity by activating desired immune responses to attack cancer cells while simultaneously blocking unwanted immunosuppressive activities.
HCW Biologics Lead Candidate Shows Preclinical Anti-Tumor Activity, Reduced Side Effects of Chemo
HCW Biologics Inc (NASDAQ: HCWB) has announced the publication of a scientific paper in Molecular Therapy highlighting preclinical data of its lead program, HCW9218. The preclinical data demonstrated that HCW9218 enhanced the anti-tumor efficacy of chemotherapy drugs and diminished their harmful side effects by reducing therapy-induced senescence (TIS).
Good Penny Stocks to Buy Right Now? 3 to Watch in November
Are these penny stocks worth buying right now? The post Good Penny Stocks to Buy Right Now?
Making a Penny Stocks Watchlist? Don't Forget These 3 Small-Caps
Three penny stocks that could be worth watching in the second half of October The post Making a Penny Stocks Watchlist? Don't Forget These 3 Small-Caps appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
HCW Biologics Showcases Scientific Paper in Molecular Therapy Highlighting Potential of HCW9218 as Novel, Bifunctional Cancer Immunotherapeutic
Lead Drug Candidate Engineered Using Tissue FactOr-Based FusIon (TOBI™) Platform
HCW Biologics' Article Published in Cancer Immunology Research Validates Novel Tissue Factor Scaffold Fusion Protein (TOBI™) Discovery Platform
TOBI™ Discovery Platform Creates GMP-Scale Heteromeric Fusion Protein Complexes (HFPCs) That Solve Issues with Multi-Signal Receptor Engagement on Immune Cells
HCW Biologics Reports Second Quarter Financial Results and Recent Business Highlights
MIRAMAR, Fla., Aug. 13, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), an innovative, biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2021.
HCW Biologics Inc. Announces Closing of $56.0 Million Initial Public Offering
MIRAMAR, Fla., July 22, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (NASDAQ:HCWB) (the "Company"), an innovative preclinical stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today announced the closing of its previously announced underwritten initial public offering of 7,000,000 shares of common stock at a public offering price of $8.00 per share for gross proceeds of $56.0 million, prior to deducting underwriting discounts, commissions, and other offering expenses. All of the shares of common stock were offered by the Company. The shares began trading on the Nasdaq Global Market on July 20, 2021, under the ticker symbol “HCWB.” In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 1,050,000 shares at the public offering price less the underwriting discounts and commissions.
HCWB Financial details
HCWB Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0.14 | 0 | 0.19 | |
Net income per share | -0.3 | -0.2 | -0.66 | -0.41 | |
Operating cash flow per share | -0.28 | -0.36 | -0.58 | -0.29 | |
Free cash flow per share | -0.34 | -0.37 | -0.59 | -0.58 | |
Cash per share | 0.3 | 0.3 | 1.96 | 0.9 | |
Book value per share | 0.37 | 0.5 | 2.73 | 1.04 | |
Tangible book value per share | 0.37 | 0.5 | 2.73 | 1.04 | |
Share holders equity per share | 0.37 | 0.5 | 2.73 | 1.04 | |
Interest debt per share | 0 | 0.02 | -0.1 | 0.18 | |
Market cap | 153.9M | 180.23M | 43.55M | 68.59M | |
Enterprise value | 146.54M | 172.34M | 31.82M | 52.68M | |
P/E ratio | -21.31 | -31.18 | -3.52 | -4.66 | |
Price to sales ratio | 0 | 43.96 | 0 | 10.2 | |
POCF ratio | -22.75 | -17.28 | -3.97 | -6.6 | |
PFCF ratio | -18.71 | -16.97 | -3.95 | -3.32 | |
P/B Ratio | 17.1 | 12.52 | 0.85 | 1.83 | |
PTB ratio | 17.1 | 12.52 | 0.85 | 1.83 | |
EV to sales | 0 | 42.04 | 0 | 7.84 | |
Enterprise value over EBITDA | -21.11 | -32.96 | -2.48 | -3.57 | |
EV to operating cash flow | -21.66 | -16.52 | -2.9 | -5.07 | |
EV to free cash flow | -17.82 | -16.23 | -2.89 | -2.55 | |
Earnings yield | -0.05 | -0.03 | -0.28 | -0.21 | |
Free cash flow yield | -0.05 | -0.06 | -0.25 | -0.3 | |
Debt to equity | 0 | 0.04 | -0.04 | 0.17 | |
Debt to assets | 0 | 0.04 | -0.03 | 0.14 | |
Net debt to EBITDA | 1.06 | 1.51 | 0.91 | 1.08 | |
Current ratio | 7.53 | 12.14 | 17.44 | 11.52 | |
Interest coverage | 0 | 0 | 0 | -119.05 | |
Income quality | 0.93 | 1.8 | 0.85 | 0.7 | |
Dividend Yield | 0 | 0 | 0.06 | 0 | |
Payout ratio | 0 | 0 | -0.23 | 0 | |
Sales general and administrative to revenue | 0 | 0.59 | 0 | 1.24 | |
Research and developement to revenue | 0 | 1.77 | 0 | 1.39 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.22 | 0.02 | 0 | 0.99 | |
Capex to revenue | 0 | -0.05 | 0 | -1.53 | |
Capex to depreciation | -3.46 | -0.31 | -0.09 | -14.31 | |
Stock based compensation to revenue | 0 | 0.01 | 0 | 0.17 | |
Graham number | 1.57 | 1.51 | 6.36 | 3.11 | |
ROIC | -0.81 | -0.39 | -0.26 | -0.34 | |
Return on tangible assets | -0.72 | -0.38 | -0.23 | -0.31 | |
Graham Net | 0.26 | 0.34 | 1.9 | 0.66 | |
Working capital | 6.96M | 11.15M | 38.16M | 31.11M | |
Tangible asset value | 9M | 14.4M | 51.19M | 37.43M | |
Net current asset value | 6.96M | 11.15M | 38.16M | 24.69M | |
Invested capital | 0 | 0.04 | -0.04 | 0.17 | |
Average receivables | 0 | 1.25M | 1.32M | 275.35K | |
Average payables | 0 | 273.84K | 189.5K | 724.91K | |
Average inventory | 0 | 269.15K | 1.37M | 1.8M | |
Days sales outstanding | 0 | 222.57 | 0 | 22.68 | |
Days payables outstanding | 339.49 | 0 | 150.18 | 108.22 | |
Days of inventory on hand | 0 | 0 | 1.47K | 123.11 | |
Receivables turnover | 0 | 1.64 | 0 | 16.09 | |
Payables turnover | 1.08 | 0 | 2.43 | 3.37 | |
Inventory turnover | 0 | 0 | 0.25 | 2.96 | |
ROE | -0.8 | -0.4 | -0.24 | -0.39 | |
Capex per share | -0.06 | -0.01 | 0 | -0.29 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.05 | 0.04 | 0 | 0.02 | 0.02 | |
Net income per share | -0.11 | -0.15 | -0.14 | -0.12 | -0.14 | |
Operating cash flow per share | -0.06 | -0.11 | -0.1 | -0.26 | -0.16 | |
Free cash flow per share | -0.35 | -0.11 | -0.11 | -0.3 | -0.17 | |
Cash per share | 0.73 | 0.89 | 0.79 | 0.48 | 0.31 | |
Book value per share | 1.19 | 1.04 | 0.91 | 0.8 | 0.66 | |
Tangible book value per share | 1.19 | 1.04 | 0.91 | 0.8 | 0.66 | |
Share holders equity per share | 1.19 | 1.04 | 0.91 | 0.8 | 0.66 | |
Interest debt per share | 0.18 | 0.18 | 0.18 | 0.18 | 0.18 | |
Market cap | 82.06M | 68.67M | 50.27M | 77.93M | 68.26M | |
Enterprise value | 62.29M | 52.75M | 38.27M | 76.84M | 63.37M | |
P/E ratio | -5.39 | -3.21 | -2.58 | -4.53 | -3.46 | |
Price to sales ratio | 45.36 | 51.19 | 1.2K | 125.12 | 80.02 | |
POCF ratio | -35.45 | -18.12 | -13.82 | -8.3 | -12.21 | |
PFCF ratio | -6.57 | -17.8 | -12.76 | -7.12 | -10.98 | |
P/B Ratio | 1.93 | 1.83 | 1.54 | 2.73 | 2.86 | |
PTB ratio | 1.93 | 1.83 | 1.54 | 2.73 | 2.86 | |
EV to sales | 34.43 | 39.32 | 913.73 | 123.37 | 74.29 | |
Enterprise value over EBITDA | -16.16 | -9.31 | -7.69 | -19.58 | -13.88 | |
EV to operating cash flow | -26.91 | -13.92 | -10.52 | -8.18 | -11.34 | |
EV to free cash flow | -4.99 | -13.67 | -9.72 | -7.02 | -10.19 | |
Earnings yield | -0.05 | -0.08 | -0.1 | -0.06 | -0.07 | |
Free cash flow yield | -0.15 | -0.06 | -0.08 | -0.14 | -0.09 | |
Debt to equity | 0.15 | 0.17 | 0.2 | 0.22 | 0.27 | |
Debt to assets | 0.13 | 0.14 | 0.15 | 0.16 | 0.18 | |
Net debt to EBITDA | 5.13 | 2.81 | 2.41 | 0.28 | 1.07 | |
Current ratio | 12.52 | 11.52 | 6.62 | 4.36 | 2.56 | |
Interest coverage | -38.12 | -267.34 | -57.37 | -47.22 | -53.16 | |
Income quality | 0.59 | 0.7 | 0.72 | 2.18 | 1.13 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.94 | 2.24 | 74.43 | 4.74 | 4.13 | |
Research and developement to revenue | 1.46 | 2.18 | 53.86 | 2.6 | 1.95 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 4.39 | 0.02 | 0.08 | 0.17 | 0.11 | |
Capex to revenue | -5.62 | -0.05 | -7.17 | -2.5 | -0.74 | |
Capex to depreciation | -61.89 | -0.26 | -1.01 | -5.47 | -2.27 | |
Stock based compensation to revenue | 0.17 | 0.21 | 6.19 | 0.42 | 0.26 | |
Graham number | 1.69 | 1.87 | 1.67 | 1.47 | 1.43 | |
ROIC | -0.08 | -0.13 | -0.13 | -0.14 | -0.18 | |
Return on tangible assets | -0.07 | -0.11 | -0.11 | -0.11 | -0.14 | |
Graham Net | 0.52 | 0.66 | 0.5 | 0.21 | 0.02 | |
Working capital | 26.41M | 31.11M | 25.42M | 15.26M | 8.43M | |
Tangible asset value | 42.56M | 37.43M | 32.62M | 28.59M | 23.87M | |
Net current asset value | 19.91M | 24.69M | 19.02M | 8.9M | 2.1M | |
Invested capital | 0.15 | 0.17 | 0.2 | 0.22 | 0.27 | |
Average receivables | 351.24K | 386.63K | 335.21K | 479.97K | 708.64K | |
Average payables | 853.28K | 1.32M | 1.2M | 1.64M | 2.64M | |
Average inventory | 1.66M | 1.66M | 1.26M | 1.24M | 1.55M | |
Days sales outstanding | 17.69 | 28.02 | 543.07 | 102.2 | 74.91 | |
Days payables outstanding | 87.71 | 102.83 | 3.57K | 379.1 | 418.45 | |
Days of inventory on hand | 119.53 | 116.98 | 3.47K | 243.01 | 231.17 | |
Receivables turnover | 5.09 | 3.21 | 0.17 | 0.88 | 1.2 | |
Payables turnover | 1.03 | 0.88 | 0.03 | 0.24 | 0.22 | |
Inventory turnover | 0.75 | 0.77 | 0.03 | 0.37 | 0.39 | |
ROE | -0.09 | -0.14 | -0.15 | -0.15 | -0.21 | |
Capex per share | -0.28 | 0 | -0.01 | -0.04 | -0.02 |
HCWB Frequently Asked Questions
What is HCW Biologics Inc. stock symbol ?
HCW Biologics Inc. is a US stock , located in Miramar of Fl and trading under the symbol HCWB
What is HCW Biologics Inc. stock quote today ?
HCW Biologics Inc. stock price is $1.72 today.
Is HCW Biologics Inc. stock public?
Yes, HCW Biologics Inc. is a publicly traded company.